Abivax SA - American Depositary Shares (ABVX)

Abivax said Phase 3 trials showed obefazimod improved clinical outcomes in ulcerative colitis, meeting key endpoints with no new safety concerns.

The company is working on a treatment for a form of inflammatory bowel disease, a highly watched disease area.

The financial markets are abuzz with significant corporate developments as several key companies navigate pivotal moments, ranging from prestigious S&P index inclusions to critical quarterly earnings reports. Robinhood Markets (NASDAQ: HOOD) and AppLovin (NASDAQ: APP) are making headlines with their impending entry into the benchmark S&P 500 index,

This little-known biotech might still deliver strong returns.

The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.

Abivax shares jump as obefazimod meets key Phase 3 trial endpoints in ulcerative colitis with strong remission rates and a favorable safety profile.

Shares of Vicor Corporation (NASDAQ:VICR) rose sharply in pre-market trading after posting second-quarter results.

The drug candidate demonstrated a placebo-adjusted remission rate of 19.3% in the first study and 13.4% in the second study.

The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.